Immunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France

Size: px
Start display at page:

Download "Immunotherapy for Melanoma. Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France"

Transcription

1 Immunotherapy for Melanoma Caroline Robert, MD, PhD Gustave Roussy and Université Paris Sud Villejuif, France

2

3 Overall Survival for Metastatic Melanoma Proportion Alive Survival data from 42 phase II trials with over 2100 stage IV patients: 12-month OS: 25.5 %, Median OS: 6.2 months Time, Months Korn EL, et al. J Clin Oncol. 2008;26(4): Dummer R, et al. Ann Oncol. 2008;19 Suppl 2:ii Garbe C, et al. Eur J Cancer. 2010;46(2):

4 Melanoma Immunotherapy Spontaneous regression Vitiligo Halo-nevus

5 High-Dose IL-2 Response rate: 15%, with 5% complete response Grades 3-5 >50% and 2% death Atkins MB, et al. J Clin Oncol. 1999;17(7):

6 Boutros C, et al. Nat Rev Clin Oncol. 2016;13(8):

7 Anti-CTLA-4: Ipilimumab Pretreated Patients +/- gp100 HLA-A2 3 mg/kg Reinduction possible Naïve Patients + DTIC 10 mg/kg Maintenance possible Hodi FS, et al. N Engl J Med. 2010;363(8): Robert C, et al. N Engl J Med. 2011;364(26):

8 Anti-CTLA-4: Ipilimumab Plateau effect Hodi FS, et al. N Engl J Med. 2010;363(8): Robert C, et al. N Engl J Med. 2011;364(26):

9 Pembrolizumab Anti-PD-1 Two Phase I Trials ORR 30 and 40% Toxicity: 15% grade 3 Nivolumab Overall Survival, % year OS 49% Time, Months n at risk at Risk Total 2-year OS 48% 3-year OS 41% Months Ribas A, et al. JAMA. 2016;3.135(15): Hodi FS, et al. J Clin Oncol. 2014;32(5s): Abstract 9002.

10 Phase III Nivolumab vs Chemotherapy Phase III Pembrolizumab vs Ipilimumab 1-yr OS 73% (n = 210) (n = 208) 1-yr OS 42% Treatment Arm Median (95% CI), mo Rate at 12 mo HR (95% CI) P Pembrolizumab Q2W NR (NR-NR) 74.1% 0.63 ( ) Pembrolizumab Q3W NR (NR-NR) 68.4% 0.69 ( ) < < Ipilimumab NR (12.7-NR) 58.2% Follow-up since randomization: months Decreased risk of death by 58% compared to chemotherapy, and by 31% to 37% compared with ipilimumab Robert C, et al. N Engl J Med. 2015;372(4): Robert C, et al. N Engl J Med. 2015;372(26):

11 Early Effect of Checkpoint Inhibitors

12 Adjuvant Treatment With Ipilimumab Eggermont AM, et al. N Engl J Med. 2016;375(19):

13 Adjuvant Treatment With Nivolumab vs Ipilimumab: CheckMate 238 Enrollment period: March 30, 2015 to November 30, 2015 Patients with high-risk, completely resected stage IIIB/IIIC or stage IV melanoma 1:1 n = 453 n = 453 Stratified by: 1) Disease stage: IIIB/C vs IV M1a-M1b vs IV M1c 2) PD-L1 status at a 5% cutoff in tumor cells NIVO 3 mg/kg IV q2w and IPI placebo IV q3w for 4 doses then q12w from week 24 IPI 10 mg/kg IV q3w for 4 doses then q12w from week 24 and NIVO placebo IV q2w Follow-up Maximum treatment duration of 1 year Weber J, et al. N Engl J Med. 2017;377(19): Weber J, et al. Ann Oncol. 2017;28(Suppl 5): Abstract LBA8_PR.

14 Nivolumab Is Superior to Ipilimumab in the Adjuvant Setting NIVO IPI Events/patients 154/ / Median (95% CI) NR NR (16.6, NR) RFS, % % 61% 66% 53% HR (97.56% CI) 0.65 (0.51, 0.83) Log-rank P value < Number of patients at risk NIVO IPI NIVO IPI Months Weber J, et al. N Engl J Med. 2017;377(19): Weber J, et al. Ann Oncol. 2017;28(Suppl 5): Abstract LBA8_PR.

15 KEYNOTE-054: Adjuvant Pembrolizumab in High-Risk Stage III Melanoma Patients with high-risk, completely resected stage III melanoma R A N D O M I Z E Pembro 200 mg IV on day 1 of each 21-day cycle Placebo IV on day 1 of each 21-day cycle Follow-up Maximum treatment duration of 1 year Primary Endpoint: Recurrence-free survival (RFS) for all participants, RFS for participants with PD-L1 positive tumor expression Secondary Endpoints: Distant metastases-free survival (DMFS) for all participants, DMFS for participants with PD-L1 positive tumor expression, OS in all participants, OS in participants with PD-L1 positive tumor expression Results expected spring 2018 National Institutes of Health. Accessed November 9, 2017.

16 CheckMate 067: Combination of Immunotherapies Progression-Free Survival Overall Survival Wolchok JD, et al. N Engl J Med. 2017;377(14):

17 First-Line Therapy: Overall Survival Mean survival curves created by weighted averaging of digitized Kaplan-Meier survival curves of metastatic melanoma patients treated in selected clinical trials. Ugurel S, et al. Eur J Cancer. 2016;53:

18 Unpublished data. Longer Follow-Up

19 Unpublished data. Longer Follow-Up

20 New Toxicity Profile

21 Which of the following adverse events would you NOT consider to be immune related in a patient receiving checkpoint inhibitor therapy for the treatment of melanoma? 1. Pneumonitis 2. Rash 3. Hypertension 4. Colitis 5. Hepatotoxicity

22 More Organs or Tissues Can Be Involved Michot JM, et al. Eur J Cancer. 2016;54:

23 But: High Toxicity of the Combination Grade 3/5 AE % Discontinuation for AE % Ipilimumab 3 mg/kg Nivolumab Pembrolizumab Ipilimumab + nivolumab Atkinson V, et al. Presented at: 9 th World Congress of Melanoma. October 18-21, Brisbane, Australia. 2. Weber J, et al. N Engl J Med. 2017;377(19): Ribas A, et al. JAMA. 2016;315(15): Wolchok JD, et al. N Engl J Med. 2017;377(14):

24 Immunotherapy Adverse Events Boutros C, et al. Nat Rev Clin Oncol. 2016;13(8):

25 Bompaire F, et al. Invest New Drugs. 2012;30(6):

26 Vitiligo With Anti-PD1 or Anti-PDL1

27 Vitiligo and Clinical Response to Pembrolizumab Patient CR PR SD PD P* Vitiligo (n = 17) 3 (18) 9 (53) 3 (18) 2 (12).002 No vitiligo (n = 50) 4 (8) 10 (20) 1 (2) 35 (70) Total (N = 67) 7 (10) 19 (28) 4 (6) 36 (54) *Complete/partial response versus stable/progressive disease/progression in patients with and without vitiligo, exact Fisher test Hua C, et al. JAMA Dermatol. 2016;152(1):45-51.

28 New Evaluation Criteria

29 New Types of Responses Wolchock JD, et al. Clin Cancer Res. 2009;15(23): Immune-Related Response Criteria

30 Baseline 12 weeks 24 weeks 52 weeks

31 New Reasons to Stop Treatment

32 Pembrolizumab Phase I: KEYNOTE-001 : Median Follow-Up 43 Months for 655 Patients On treatment: 16% Consent withdrawal 5% Discontinue for physician decision 11% Discontinued for PD: 42% Discontinued for AEs: 25% Range of follow-up: months. Analysis cutoff date: September 1, Robert C, et al. Presented at: 13 th Congress of the European Association of Dermato Oncology; May 3-6, 2017; Athens, Greece.

33 Complete Responders: Disposition Median follow-up: 43 months 92 (88%) remained in CR a 105 (16%) patients had CR per irrc by investigator review 14 (13%) remained on pembrolizumab 24 (23%) discontinued for AEs (n = 12), PD (n = 2), or other reason (n = 10) 67 (64%) stopped pembrolizumab for observation a Patient was alive and without disease progression. Analysis cutoff date: September 1, Robert C, et al. Presented at: 13 th Congress of the European Association of Dermato Oncology; May 3-6, 2017; Athens, Greece.

34 Complete Responders Who Stopped Pembrolizumab for Observation (N = 67) Median time to CR: 13 mo ( 3-36 mo) 61 (91%) responses were maintained Median response duration: NR (6+ to 56+ mo) Time to PD or last assessment Last dose CR PR PD Time to death Time, months Total bar length represents the time to the last scan. Analysis cutoff date: September 1, Robert C, et al. Presented at: 13 th Congress of the European Association of Dermato Oncology; May 3-6, 2017; Athens, Greece.

35 In KEYNOTE-006, what is the estimated PFS at follow-up in patients who completed protocolspecified time on treatment? 1. 61% 2. 71% 3. 81% 4. 91%

36 KEYNOTE-006 (NCT ) Patients Unresectable, stage III or IV melanoma 1 previous therapy, excluding anti CTLA-4, PD-1, or PD-L1 agents Known BRAF mutation status a ECOG PS 0-1 No active brain metastases No serious autoimmune disease R 1:1:1 Pembrolizumab 10 mg/kg intravenous q2w for 2 years Pembrolizumab 10 mg/kg intravenous q3w for 2 years Ipilimumab 3 mg/kg intravenous q3w 4 doses Stratification Factors ECOG PS (0 vs 1) Line of therapy (first vs second) PD-L1 status b (positive vs negative) Primary endpoints: PFS and OS Secondary endpoints: ORR, duration of response, safety Robert C, et al. J Clin Oncol. 2017;35(suppl): Abstract a Prior anti-braf targeted therapy was not required for patients with normal LDH levels and no clinically significant tumor-related symptoms or evidence of rapidly progressing disease. b Defined as 1% staining in tumor and adjacent immune cells as assessed by IHC (22C3 antibody).

37 KEYNOTE-006: Patients Who Completed Protocol-Specified Time on Pembrolizumab (Median Follow-Up, 9.7 mo) 556 patients received pembrolizumab 104 (19%) completed pembrolizumab 24 (23%) CR 68 (65%) PR 12 (12%) SD 23 ongoing responses 1 PD b 1 received second course of pembrolizumab 64 ongoing responses 4 PD b 3 received second course of pembrolizumab 10 ongoing SD 2 deaths b,c Robert C, et al. J Clin Oncol. 2017;35(suppl): Abstract a Includes patients completing 21.6 months of treatment. b From end of pembrolizumab treatment. c Both deaths were a result of PD. Data cutoff date: Nov 3, 2016.

38 PFS (irrc, Investigator) From Last Pembrolizumab Dose in Patients Who Completed Protocol-Specified Time on Treatment (n = 104) Progression-Free Survival, % Patients Who Completed Protocol-Specified Time on Pembrolizumab, n Estimated PFS, % (95% CI) 102 (98%) patients were alive after a median of 9.7 months after completing pembrolizumab treatment Median PFS (80-96) NR No. at risk Time, Months Robert C, et al. J Clin Oncol. 2017;35(suppl): Abstract Data cutoff date: Nov 3, 2016.

39 Ipilimumab + Nivolumab: Pooled Data From CheckMate 067 and 69 Schadendorf D, et al. J Clin Oncol Aug 25. [Epub ahead of print].

40 Ipilimumab + Nivolumab: Pooled Data From CheckMate 067 and 09 PFS and OS not significantly different between the patients who discontinued for AE during the induction period and those who did not discontinue Schadendorf D, et al. J Clin Oncol Aug 25. [Epub ahead of print].

41 Ipilimumab + Nivolumab: Pooled Data From CheckMate 067 and 09 Patients who discontinued treatment because of adverse events during the induction phase of treatment. Schadendorf D, et al. J Clin Oncol Aug 25. [Epub ahead of print].

42 To Improve Benefit/Risk Ratio Recent Results on Combinations Combination targeted therapy + anti PD1/PDL-1 Cobimetinib/vemurafenib/atezolizumab Dabrafenib/trametinib/pembrolizumab Combination of immunotherapies Pembrolizumab/ipilimumab 1 mg/kg Pembrolizumab/TVEC Pembrolizumab/anti-IDO epacadostat In anti-pd1 refractory patients Nivolumab/anti-Lag3 relatlimab

43 Early Combination Studies KEYNOTE Pembro + Dabra + Trame GP Cobi + Vemu + Atezo KEYNOTE Pembro + Epacadostat KEYNOTE Pembro + Ipi1 mg Pembro + TVEC 5 Nivo+ Relatlimab 6 N High LDH (%) NR M1C (%) * 47.5 ORR (%) CR (%) ** 1.6 Grade 3/5 AE (%) Median FU (months) * But 44% III or M1a; ** including injected lesions 1. Ribas A, et al. Ann Oncol. 2017;28(Suppl 6): Abstract 1216O. 2. Hwu P, et al. Ann Oncol. 2016;27(Suppl 6): Abstract 1109PD. 3. Hamid O, et al. Ann Oncol. 2017;28(Suppl 6): Abstract 1214O. 4. Long GV, et al. Lancet Oncol. 2017;18(9): Ribas A, et al. Cell. 2017;170(6): Ascierto PA, et al. Ann Oncol. 2017;28(Suppl 6): Abstract LBA18.

44 New Biomarkers

45 PD-L1 High Expression Associated With Clinical Response to Anti-PD1 100 ORR, RECIST v1.1 Correlation between PD-L1 expression and ORR (P<.0001) ORR, % (95% CI) PD-L1 Negative 0% Staining APS = 0 PD-L1 Positive 1-10% Staining APS = 2 APS, Allred proportion score. Analysis cut-off date: October 18, PD-L1 Positive 10-33% Staining APS = 3 PD-L1 Positive % Staining APS = APS 0 n = 28 APS 1 n = 24 Negative Daud A. Presented at: 2015 American Society of Clinical Oncology Annual Meeting: Clinical Science Symposium Intersection of the Mutanome and the Immunome; May 29-June 2, 2015; Chicago, Illinois. APS 2 n = 72 APS 3 n = 54 APS 4 n = 32 Positive APS 5 n = 34

46 Which of the following is NOT a difference between PD-L1 testing platforms? 1. PD-L1 expression level cutoff 2. Use of immune cells for expression testing 3. Use of tumor cells for expression testing 4. Antibody used for testing

47 Heterogeneity of PD-L1 IHC Assays Clone Species Assay Developer Treatment Drug Target 22C3 Mouse Dako Pembrolizumab PD Rabbit Dako Nivolumab PD-1 SP142 Rabbit Ventana Atezolizumab PD-L1 Relevant Cutoff From Clinical Trials TC 5% (melanoma) Any intensity TC 1% Any intensity TC 50%/5%/1% Moderate and strong intensity IC 10%/5%/1% SP263 Rabbit Ventana Durvalumab PD-L1 TC 25% Any intensity 04/12/2017 TC, tumor cells; IC: immune cells Courtesy Julien Adam, Gustave Roussy Other antibodies - 5H1 (Lieping Chen), mouse mab - E1L3N (Cell signaling technology), rabbit mab

48 Courtesy Julien Adam, Gustave Roussy

49 Among Several Markers, CD8+ Was the Most Predictive for Response to Pembrolizumab Tumeh PC, et al. Nature. 2014;515(7528):

50 Role of the Gut Microbiota? Baseline microbiota type is linked to the risk of colitis and response to immunotherapy Chaput N, et al. Ann Oncol. 2017;28(6):

51 Mutational Load and Neoantigens Number of nonsynonymous mutations Generation of neoantigens Anti-CTLA-4 in Melanoma Snyder A, et al. N Engl J Med. 2014;371(23): Rizvi NA, et al. Science. 2015;348(6230): Anti-PD-1 in NSCLC

52 Mutational Load and Neoantigens Alexandrov LB, et al. Nature. 2013;500(7463): Schumacher TN, et al. Science. 2015;348(6230):69-74.

53 New Mechanisms of Resistance

54 Genetic Resistances to Immunotherapies Mutation-derived modification of the INF-γ signaling pathway or loss of Cl I expression Zaretsky JM, et al. N Engl J Med. 2016;375(9): Gao J, et al. Cell. 2016;167(2):

55 Many Avenues Are Explored to Overcome the Resistance + radiotherapy + other IT 41BB OX-40 CD40 GITR ICOS IDO + other checkpoint-i TIM 3; LAG 3 + macrophage-i CSFR1 + chemo + local tt Ipi Oncol virus TLR agonist + cancer vaccines + Adopt C T + targeted therapies BRAF, MEK + epigenetic modifiers HDAC + NK activation

56 Genetic background: MHC DNA-repair system Immune background Tumor specific: Mutations, neoantigens DNA-repair capacity Immune targets: PD1, PDL-1, Lag-3 Metabolism: LDH, oxphos, glycolysis Translation initiation Microbiome Gut Skin Immune landscape : Immunoscore: CTL, repertoire, Treg, B cells, Tfh, MDSC, Immune biomarkers: PD1, PDL-1, PLA Lag-3,

57 This is the revolution Conclusion Real hope to cure some patients For some others, nothing has changed (high LDH, multiple brain metastases) We have to continue Clinical trials with translational research Combination, or sequences of drugs Biomarker identification

58 Clinical and Research Teams

Immunotherapy of Melanoma Sanjiv S. Agarwala, MD

Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma

More information

Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania

Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Immunotherapy in Unresectable or Metastatic Melanoma: Where Do We Stand? Sanjiv S. Agarwala, MD St. Luke s Cancer Center Bethlehem, Pennsylvania Overview Background Immunotherapy clinical decision questions

More information

Medical Treatment for Melanoma Sanjiv S. Agarwala, MD

Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview

More information

What we learned from immunotherapy in the past years

What we learned from immunotherapy in the past years What we learned from immunotherapy in the past years Paolo A. Ascierto, MD Unit Melanoma, Cancer Immunotherapy and Innovative Therapies Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy Disclosure

More information

Update on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017

Update on Immunotherapy in Advanced Melanoma. Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 Update on Immunotherapy in Advanced Melanoma Ragini Kudchadkar, MD Assistant Professor Winship Cancer Institute Emory University Sea Island 2017 1 Outline Adjuvant Therapy Combination Immunotherapy Single

More information

Immunotherapy, an exciting era!!

Immunotherapy, an exciting era!! Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy

More information

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital

Immunotherapy for the Treatment of Melanoma. Marlana Orloff, MD Thomas Jefferson University Hospital Immunotherapy for the Treatment of Melanoma Marlana Orloff, MD Thomas Jefferson University Hospital Disclosures Immunocore and Castle Biosciences, Consulting Fees I will be discussing non-fda approved

More information

III Sessione I risultati clinici

III Sessione I risultati clinici 10,30-13,15 III Sessione I risultati clinici Moderatori: Michele Maio - Valter Torri 10,30-10,45 Melanoma: anti CTLA-4 Vanna Chiarion Sileni Vanna Chiarion Sileni IOV-IRCCS,Padova Vanna.chiarion@ioveneto.it

More information

New paradigms for treating metastatic melanoma

New paradigms for treating metastatic melanoma New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall

More information

Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.

Out of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates. 6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes

More information

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States

Immunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy

More information

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology

Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Current Trends in Melanoma Theresa Medina, MD UCD Cutaneous Oncology Overview Melanoma incidence and prevention Approach to surgical management of early melanoma Landscape of Advanced Melanoma Therapy

More information

Immunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg

Immunotherapy for Metastatic Malignant Melanoma. Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Immunotherapy for Metastatic Malignant Melanoma Dr Daniel A Vorobiof Sandton Oncology Centre Johannesburg Survival in Melanoma by Stage Proportion Surviving 1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2 0.1 Stage

More information

Patient Selection: The Search for Immunotherapy Biomarkers

Patient Selection: The Search for Immunotherapy Biomarkers Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic

More information

Melanoma: Immune checkpoints

Melanoma: Immune checkpoints ESMO Preceptorship Programme Immuno-Oncology Siena, July 04-05, 2016 Melanoma: Immune checkpoints Michele Maio Medical Oncology and Immunotherapy-Department of Oncology University Hospital of Siena, Istituto

More information

MELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona

MELANOMA METASTASICO: NUEVAS COMBINACIONES. Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona MELANOMA METASTASICO: NUEVAS COMBINACIONES Dr Ana Arance MD PhD Oncología Médica Hospital Clínic Barcelona Summary of OS accross clinical trials in patients with metastatic melanoma Ugurel et al. Eur J

More information

Incorporating Immunotherapy into the treatment of NSCLC

Incorporating Immunotherapy into the treatment of NSCLC Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute

More information

O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra

O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal. Gabriela Sousa Oncologia Médica IPO Coimbra O DESAFIO DA INOVAÇÃO EM ONCOLOGIA EM PORTUGAL The Challenges of innovative oncology care in Portugal Gabriela Sousa Oncologia Médica IPO Coimbra Incidência aumenta 3% ao ano Envelhecimento populacional

More information

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health

Checkpoint regulators a new class of cancer immunotherapeutics. Dr Oliver Klein Medical Oncologist ONJCC Austin Health Checkpoint regulators a new class of cancer immunotherapeutics Dr Oliver Klein Medical Oncologist ONJCC Austin Health Cancer...Immunology matters Anti-tumour immune response The participants Dendritc cells

More information

Conversations in Oncology. November Kerry Hotel Pudong, Shanghai China

Conversations in Oncology. November Kerry Hotel Pudong, Shanghai China Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not

More information

Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3

Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 MELANOMA AND OTHER SKIN TUMOURS... 3 Long-term results show adjuvant therapy with ipilimumab improves OS in high

More information

CheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer

CheckMate 012: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer CheckMate 12: Safety and Efficacy of First Line Nivolumab and Ipilimumab in Advanced Non-Small Cell Lung Cancer Abstract 31 Hellmann MD, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE,

More information

Immunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center

Immunotherapy for Melanoma. Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Immunotherapy for Melanoma Michael Postow, MD Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center Conflicts of Interest Bristol-Myers Squibb: -Research support -Participated

More information

Developping the next generation of studies in RCC

Developping the next generation of studies in RCC Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,

More information

Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento

Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Il ruolo di PD-L1 (42%) tra la prima e la seconda linea di trattamento Alessia Pochesci Divisione di Oncologia Toracica Istituto Europeo di Oncologia, Milano Tutor: Prof.ssa Silvia Novello Dott.ssa Chiara

More information

Emerging Tissue and Serum Markers

Emerging Tissue and Serum Markers Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice

More information

Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma

Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Optimizing Immunotherapy New Approaches, Biomarkers, Sequences and Combinations Immunotherapy in the clinic Melanoma Dr. J.L.Manzano S. Oncología Médica H. Germans Trias i Pujol, ICO-Badalona PRBB Auditorium,

More information

Immunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto

Immunoterapia e melanoma maligno metastatico: siamo partiti da li. Vanna Chiarion Sileni Istituto Oncologico Veneto Immunoterapia e melanoma maligno metastatico: siamo partiti da li Vanna Chiarion Sileni Istituto Oncologico Veneto Vanna.chiarion@iov.veneto.it Metastatic Melanoma Available Treatment: 197 217 Zelboraf

More information

Treatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC

Treatment and management of advanced melanoma: Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Treatment and management of advanced melanoma: 2018 Paul B. Chapman, MD Melanoma Clinical Director, Melanoma and Immunotherapeutics Service MSKCC Disclosure Paul B. Chapman, MD Nothing to disclose. Off

More information

Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1

Melanoma. Il parere dell esperto. V. Ferraresi. Divisione di Oncologia Medica 1 Melanoma Il parere dell esperto V. Ferraresi Divisione di Oncologia Medica 1 MELANOMA and ESMO 2017.what happens? New data and updates ADJUVANT THERAPY with CHECKPOINT INHIBITORS (CA209-238 trial) AND

More information

Combination Approaches in Melanoma: A Balancing Act

Combination Approaches in Melanoma: A Balancing Act Combination Approaches in Melanoma: A Balancing Act Antoni Ribas, MD, PhD Jonsson Comprehensive Cancer Center University of California Los Angeles Los Angeles, California Advances in the Treatment of Metastatic

More information

Immunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)

Immunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS) Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers

More information

A Giant Leap in the Treatment Options for Advanced Bladder Cancer

A Giant Leap in the Treatment Options for Advanced Bladder Cancer A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer

More information

Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin

Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors

More information

Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes

Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Immune Checkpoint Therapy Toxicities: Lessons learned and new strategies to improve outcomes Geoffrey T. Gibney, MD Associate Professor Co-leader, Melanoma Disease Group Lombardi Comprehensive Cancer Center

More information

The Immunotherapy of Oncology

The Immunotherapy of Oncology The Immunotherapy of Oncology The 30-year Overnight Success Story M Avery, BIOtech Now 2014 Disclosures: Geoffrey R. Weiss, M.D. None The History A. Chekov: It has long been noted that the growth of malignant

More information

Renal Cell Carcinoma: Systemic Therapy Progress and Promise

Renal Cell Carcinoma: Systemic Therapy Progress and Promise Renal Cell Carcinoma: Systemic Therapy Progress and Promise Michael B. Atkins, M.D. Deputy Director, Lombardi Comprehensive Cancer Ctr Georgetown University Medical Center Everolimus Rini, Campbell, Escudier.

More information

Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016

Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Advances in Cancer Immunotherapy for Solid Tumors Expert Perspectives on The New Data Sunday, June 5, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016

More information

Principles and Application of Immunotherapy for Cancer: Advanced NSCLC

Principles and Application of Immunotherapy for Cancer: Advanced NSCLC In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced NSCLC This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged

More information

Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico

Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Terapia Immunomodulante e Target Therapies nel Trattamento del Melanoma Metastatico Pier Francesco Ferrucci Direttore, Unità di Oncologia Medica del Melanoma Istituto Europeo di Oncologia - Milano Pisa,

More information

ASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine

ASCO 2014: The Future is Here. What I Will Talk About. George W. Sledge MD Stanford University School of Medicine ASCO 214: The Future is Here George W. Sledge MD Stanford University School of Medicine What I Will Talk About Two paths to a Cure Slicing the pie MelMng the snowflake The Past Isn t Dead Improving PaMent

More information

Review of immunotherapy in melanoma

Review of immunotherapy in melanoma Review of immunotherapy in melanoma Surein Arulananda, 1,2,3 Elizabeth Blackley, 1 Jonathan Cebon 1,2,3 1. Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia. 2. Cancer Immunobiology

More information

Weitere Kombinationspartner der Immunotherapie

Weitere Kombinationspartner der Immunotherapie 1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for

More information

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian

Metastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in

More information

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb

The Current Status of Immune Checkpoint Inhibitors: Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb The Current Status of Immune Checkpoint Inhibitors: A Global Overview of the Field Arvin Yang, MD PhD Oncology Global Clinical Research Bristol-Myers Squibb Immune Checkpoint Inhibitors Conference, March

More information

Immunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington

Immunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =

More information

Presentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background

Presentation Number: LBA18_PR. Lecture Time: 09:15-09:27. Speakers: Heinz-Josef J. Lenz (Los Angeles, US) Background LBA18_PR - Durable Clinical Benefit With Nivolumab (NIVO) Plus Low-Dose Ipilimumab (IPI) as First-Line Therapy in Microsatellite Instability-High/Mismatch Repair Deficient (MSI-H/dMMR) Metastatic Colorectal

More information

MELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone

MELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year

More information

Atezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1

Atezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1 Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson

More information

ONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing

ONCOS-102 in melanoma Dr. Alexander Shoushtari. 4. ONCOS-102 in mesothelioma 5. Summary & closing ONCOS-102 in melanoma Dr. Alexander Shoushtari 4. ONCOS-102 in mesothelioma 5. Summary & closing 1 Preliminary data from C824 Activating the Alexander Shoushtari, MD Assistant Attending Physician Melanoma

More information

IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS

IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS IMMUNOTHERAPY FOR GASTROINTESTINAL CANCERS Dr Elizabeth Smyth Cambridge University Hospitals NHS Foundation Trust ESMO Gastric Cancer Preceptorship Valencia 2018 DISCLOSURES Honoraria for advisory role

More information

Melanoma Clinical Trials and Real World Experience

Melanoma Clinical Trials and Real World Experience Melanoma Clinical Trials and Real World Experience Paul Lorigan University of Manchester Manchester, UK www.christie.nhs.uk/melanoma Melanoma Bridge, Naples 214 New Benchmarks for Phase II Trials OS at

More information

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)

NSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in

More information

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know

Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Immunotherapy in the Adjuvant Setting for Melanoma: What You Need to Know Jeffrey Weber, MD, PhD Laura and Isaac Perlmutter Cancer Center NYU Langone Medical Center New York, New York What Is the Current

More information

WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example

WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example YIDOU ZHANG Health Economics and Payer Analytics Director Oncology Payer Evidence and Pricing, AstraZeneca

More information

PTAC meeting held on 5 & 6 May (minutes for web publishing)

PTAC meeting held on 5 & 6 May (minutes for web publishing) PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and

More information

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications

More information

Immunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University

Immunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,

More information

Recent Therapeutic Advances for Thoracic Malignancies

Recent Therapeutic Advances for Thoracic Malignancies Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation

More information

Brain mets under I.O.

Brain mets under I.O. Brain mets under I.O. Bernard Escudier Gustave Roussy, Villejuif, France Disclosure Honorarium received from BMS, Novartis, Pfizer, Bayer, Roche, Exelixis, Ipsen, Eisai, Calithera Travel Grant from BMS,

More information

Principles and Application of Immunotherapy for Cancer: Advanced Melanoma

Principles and Application of Immunotherapy for Cancer: Advanced Melanoma In Partnership With Principles and Application of Immunotherapy for Cancer: Advanced Melanoma This program is supported by educational grants from Genentech and Merck. About These Slides Users are encouraged

More information

Priming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics

Priming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer

More information

6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC)

6/7/16. Melanoma. Updates on immune checkpoint therapies. Molecularly targeted therapies. FDA approval for talimogene laherparepvec (T- VEC) Melanoma John A Thompson MD July 17, 2016 Featuring: Updates on immune checkpoint therapies Molecularly targeted therapies FDA approval for talimogene laherparepvec (T- VEC) 1 Mechanism of ac-on of Ipilimumab

More information

Kombination von Checkpointinhibitoren beim malignen Melanom

Kombination von Checkpointinhibitoren beim malignen Melanom Kombination von Checkpointinhibitoren beim malignen Melanom Dirk Jäger Medizinische Onkologie Nationales Centrum für Tumorerkrankungen Universitätsklinikum Heidelberg Ipilimumab beim metastasierten Melanom

More information

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese

II sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy

More information

Immune checkpoint blockade in lung cancer

Immune checkpoint blockade in lung cancer Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data

More information

New Therapeutic Approaches to Malignant Melanoma

New Therapeutic Approaches to Malignant Melanoma 2018 Master Class for Oncologists New Therapeutic Approaches to Malignant Melanoma F. Stephen Hodi, M.D. Dana-Farber Cancer Institute, Boston, MA Disclosure I have nothing to disclose. Off Label/Investigational

More information

The Really Important Questions Current Immunotherapy Trials are Not Answering

The Really Important Questions Current Immunotherapy Trials are Not Answering The Really Important Questions Current Immunotherapy Trials are Not Answering David McDermott, MD Beth Israel Deaconess Medical Center Dana Farber/Harvard Cancer Center Harvard Medical School PD-1 Pathway

More information

Bristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA

Bristol-Myers Squibb, Braine-l Alleud, Belgium; 12 MD Anderson Cancer Center, Houston, TX, USA 3531 Combination of nivolumab (NIVO) + ipilimumab (IPI) in the treatment of patients (pts) with deficient DNA mismatch repair (dmmr)/high microsatellite instability (MSI-H) metastatic colorectal cancer

More information

Largos Supervivientes, Tenemos datos?

Largos Supervivientes, Tenemos datos? Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot

More information

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System

Immunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,

More information

IMMUNOTARGET THERAPY: ASPETTI GENERALI

IMMUNOTARGET THERAPY: ASPETTI GENERALI IMMUNOTARGET THERAPY: ASPETTI GENERALI Alessandro Minisini Dipartimento di Oncologia Azienda Ospedaliero Universitaria Udine Verona, 19 settembre 2015 HALLMARKS OF CANCER Douglas Hanahan, Robert A. Weinberg,

More information

Melanoma: Therapeutic Progress and the Improvements Continue

Melanoma: Therapeutic Progress and the Improvements Continue Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic

More information

Melanoma: What else beyond Checkpoint Inhibitor pathway?

Melanoma: What else beyond Checkpoint Inhibitor pathway? Melanoma: What else beyond Checkpoint Inhibitor pathway? Jose Lutzky MD, FACP Director, Mount Sinai Melanoma Program Miami Beach, Florida Clinical Associate Professor, Wertheim School of Medicine, FIU,

More information

Immunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017

Immunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017 Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in

More information

Immune checkpoint inhibition in melanoma. John Haanen

Immune checkpoint inhibition in melanoma. John Haanen Immune checkpoint inhibition in melanoma John Haanen ESMO Preceptorship Singapore 217 Immune Checkpoint inhibitors Immune checkpoints play an important role in immune tolerance Cancer hijacks many of these

More information

New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy

New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy New Frontiers in Metastatic Melanoma: A Closer Look at the Role of Immunotherapy Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology

More information

A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma

A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma A Case Study: Ipilimumab in Pre-treated Metastatic Melanoma Tai-Tsang Chen, PhD Global Biometric Sciences, Bristol-Myers Squibb EFSPI Statistical Meeting on Evidence Synthesis Brussels, Belgium November

More information

Immunotherapy in non-small cell lung cancer

Immunotherapy in non-small cell lung cancer Immunotherapy in non-small cell lung cancer Geoffrey Peters and Thomas John Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia. Email: Geoffrey.peters@austin.org.au Abstract

More information

IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER

IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix

More information

Immune checkpoint inhibition in melanoma

Immune checkpoint inhibition in melanoma Immune checkpoint inhibition in melanoma John Haanen ESMO Preceptorship Zürich 217 Disclosures I have provided consultation, attended advisory boards, and/or provided lectures for: Pfizer, MSD, BMS, IPSEN,

More information

INMUNOTERAPIA I. Dra. Virginia Calvo

INMUNOTERAPIA I. Dra. Virginia Calvo INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:

More information

Cancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015

Cancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director

More information

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer

Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual

More information

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr.

Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy

More information

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)

Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program

More information

Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL

Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro. Immune checkpoint inhibition in DLBCL Mariano Provencio Servicio de Oncología Médica Hospital Universitario Puerta de Hierro Immune checkpoint inhibition in DLBCL Immunotherapy: The Cure is Inside Us Our immune system prevents or limit infections

More information

Debate 1 Are treatments for small cell lung cancer getting better? No:

Debate 1 Are treatments for small cell lung cancer getting better? No: Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University

More information

Overview: Immunotherapy in CNS Metastases

Overview: Immunotherapy in CNS Metastases Overview: Immunotherapy in CNS Metastases Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland Clinic Disclosures Consultant- Monteris

More information

Immunotherapy for Renal Cell Carcinoma. James Larkin

Immunotherapy for Renal Cell Carcinoma. James Larkin Immunotherapy for Renal Cell Carcinoma James Larkin Disclosures Institutional research support: BMS, MSD, Novartis, Pfizer Consultancy (all non-remunerated): Eisai, BMS, MSD, GSK, Pfizer, Novartis, Roche/Genentech

More information

Immuno-Oncology Applications

Immuno-Oncology Applications Immuno-Oncology Applications Lee S. Schwartzberg, MD, FACP West Clinic, P.C.; The University of Tennessee Memphis, Tn. ICLIO 1 st Annual National Conference 10.2.15 Philadelphia, Pa. Financial Disclosures

More information

Predictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.

Predictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D. Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell

More information

Disclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor

Disclosures. Immunotherapyin Head & NeckCancer. Actual landscape of systemic treatment in HNSCC. Head andneckcanceris an immunogeneic tumor Immunotherapyin Head & NeckCancer Disclosures Astra-Zeneca/medimmune: clinical trial BMS: advisory board, clinical trial Merck: advisory board, clinical trial, research funding Carla van Herpen Medical

More information

News from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital

News from ASCO. Niven Mehra, Medical Oncologist. Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital News from ASCO Niven Mehra, Medical Oncologist Radboud UMC Institute of Cancer Research and The Royal Marsden Hospital Disclosures Speaker fees: Merck, Bayer Advisory boards: Janssen-Cilag Research and

More information

Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico.

Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Nuovi approcci immunoterapici nel trattamento del Melanoma: Background immunologico. Andrea Anichini Human Tumors Immunobiology Unit Dept. of Experimental Oncology and Molecular Medicine Immune checkpoint

More information

New Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor

New Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research

More information

Immunotherapy in Patients with Non-Small Cell Lung Cancer

Immunotherapy in Patients with Non-Small Cell Lung Cancer LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings

More information

Best Practices in the Treatment and Management of Metastatic Melanoma. Melanoma

Best Practices in the Treatment and Management of Metastatic Melanoma. Melanoma Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant

More information

Updates in Immunotherapy for Urothelial Carcinoma

Updates in Immunotherapy for Urothelial Carcinoma Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents

More information

Cancer Immunotherapy in the Modern Era. David R. Spigel, MD Sarah Cannon Research Institute Nashville, Tennessee

Cancer Immunotherapy in the Modern Era. David R. Spigel, MD Sarah Cannon Research Institute Nashville, Tennessee Cancer Immunotherapy in the Modern Era David R. Spigel, MD Sarah Cannon Research Institute Nashville, Tennessee Key Events in the History of Cancer Immunotherapy 1890 First cancer vaccine developed (Coley)

More information